/C O R R E C T I O N - WallachBeth Capital LLC/
Key Highlights
- ➤ABVC closed private placement generating approximately $3.39 million gross proceeds
- ➤17.5% OID notes carry $4,106,060 principal and mature June 30, 2027
- ➤Notes become convertible after eight months at 85% of three-day VWAP average
- ➤ABVC will use proceeds partly for a $625,000 Lind Global Fund II settlement payment
In the news release, WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million, issued 02-Nov-2026 by WallachBeth Capital LLC over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows: WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million
JERSEY CITY, N.J., Nov. 2, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), has closed a private placement of original issue discount senior convertible promissory notes ("OID Notes") pursuant to a securities purchase agreement with institutional and other accredited investors, generating aggregate gross proceeds of approximately $3.39 million, before placement agent fees and other offering expenses.
Get started
Create a free account to read the full story.